Tag: weak

Sales weak in Q1; will meet Rs 14k cr target in FY24: Godrej Prop chairman

Realty firm Godrej Properties’ sales performance remained muted in April-June, but the company will meet the annual target to sell properties worth Rs 14,000 crore this fiscal as housing demand continues to be strong, its Executive Chairman Pirojsha Godrej said. Its sales bookings fell 11 per cent year-on-year during the first quarter of… Continue reading Sales weak in Q1; will meet Rs 14k cr target in FY24: Godrej Prop chairman

KSB zooms 19% in a weak market on healthy June quarter performance

Shares of KSB hit a new high of Rs 2,730.70, zooming 19 per cent on the BSE in Thursday’s intra-day trade, in an otherwise weak market, after the company reported healthy performance in June quarter (Q2FY24). In the past three weeks, the stock has rallied 35 per cent. Today, the stock surpassed its previous high… Continue reading KSB zooms 19% in a weak market on healthy June quarter performance

UPL slips 5%, hits over 2-year low on weak June quarter results

Shares of UPL hit an over two-year low of Rs 590.10, as they slipped 5 per cent on the BSE in Thursday’s intra-day trade after the company reported a weak set of numbers for the June quarter (Q1FY24). The stock of pesticides & agrochemicals company was trading at its lowest level since March 2021. Thus… Continue reading UPL slips 5%, hits over 2-year low on weak June quarter results

Goodyear India’s Q1 profit rises as low rubber prices offsets weak demand

BENGALURU (Reuters) – Tyre manufacturer Goodyear India reported a higher quarterly profit as a drop in raw material prices helped make up for its first revenue fall in 12 quarters on low demand. The Indian unit of U.S.-based Goodyear Tire and Rubber Co said standalone profit rose 4% to 392.6 million rupees ($4.8… Continue reading Goodyear India’s Q1 profit rises as low rubber prices offsets weak demand

Sun Pharma Q1 profit may be weighed by weak US specialty sales and Taro nos

Drugmaker Sun Pharmaceutical Industries (Sun Pharma) is expected to report a muted net profit for the June quarter (Q1FY24) when it announces its earnings on Thursday, August 3.  The pressure on earnings is likely due to flat growth for the arm Taro Pharma, weak US generic sales as a result of product restrictions at… Continue reading Sun Pharma Q1 profit may be weighed by weak US specialty sales and Taro nos

Mix of weak demand, low realisations

The weak April-June quarter (first quarter, or Q1) results of the largest listed specialty chemical maker, SRF, and multiple global headwinds for the sector are expected to weigh on the prospects of Indian specialty chemical companies in 2023-24 (FY24). Stocks in the sector (down 7–18 per cent) have underperformed the benchmarks (up over 10… Continue reading Mix of weak demand, low realisations